Having trouble accessing articles? Reset your cache.

Kappaproct: Completed Phase III enrollment

InDex completed enrollment of 120 treatment-refractory UC patients in the double-blind, placebo-controlled,

Read the full 127 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE